By Fineline Cube 
Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing round. The round was led by Shunwei Capital, with participation from Northern Light Venture Capital (NLVC), Han Kang Capital, Everest VC, Songqing Capital, and Lingang Lanwan Capital. Existing investors, including HighLight Capital (HLC), Shanghai Healthcare Capital (SHC), Delian Capital, Legend Star, and Zoo Capital, also increased their commitments. This funding will accelerate the advancement of Velavigo’s core programs into global clinical trials and bolster the development of its first-in-class (FIC) and best-in-class (BIC) drug candidates.
Company Overview
Velavigo is a leading biotech company specialized in antibody and antibody-drug conjugate (ADC) discovery and development. The company boasts a highly efficient discovery engine and robust capabilities in translational medicine, CMC, and early clinical development.
Business Model and Pipeline
Velavigo employs a dual-engine model combining in-house innovation with global partnerships. This strategy has enabled the company to build a globally competitive pipeline, with over ten programs reaching the preclinical candidate (PCC) stage. The lead oncology program is on track to enter clinical trials in both China and the U.S. in 2025.-Fineline Info & Tech